GKOS at a glance
GLAUKOS Corp (GKOS, SEC CIK 1192448) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), GLAUKOS Corp (GKOS) reported revenue of $507.4 million (up 32.3% from FY2024) and a net loss of $187.7 million. Diluted EPS was -$3.28.
- As of September 30, 2026, 33 institutional investment managers tracked by SignalX reported holding GLAUKOS Corp (GKOS) shares worth $4.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Thurman Alex R. on November 18, 2026 of 2,021 shares at $237.43 per share.
- In the last 90 days, GKOS insiders reported 0 open-market purchases ($0) and 56 open-market sales ($72.0M) on Form 4, a net sale of $72.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $507.4M
- +32.3% vs prior year
- Insiders · 90 days
- 0 buys · 56 sells
- Net −$72.0M
- 13F holders
- 33 funds
- $4.3B · −1 vs prior quarter
- Latest 8-K
- Nov 6, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development, manufacturing, and commercialization of ophthalmic surgical implants and pharmaceutical therapies
- New product emphasis: Commercial launch of iDose TR implant in early 2024 and FDA approval plus planned commercialization of Epioxa pharmaceutical therapy in early 2026
- Strategic risk exposure: Increased vulnerability to geopolitical conflicts, economic volatility, and supply chain disruptions impacting manufacturing and regulatory processes
- Quantitative metric: Accumulated deficit of approximately $933.1 million as of December 31, 2025 reflecting ongoing investment and operating losses
- Noteworthy fact: First-time FDA approval of Epioxa in October 2025, an incision-free keratoconus treatment alternative, marking significant product portfolio expansion
Risk Factors
- Regulatory risk: U.S. FDA approval of Epioxa in October 2025 requires securing permanent HCPCS J-Code and commercial payer coverage for reimbursement
- Macroeconomic risk: U.S. tariffs on imports from Canada, Mexico, and China, despite limited exposure, risk escalating trade disputes affecting sourcing costs
- Supply chain risk: Vendor supply shortages and labor disruptions causing longer lead times and higher raw material costs, impacting gross margins and product availability
- Competitive risk: Royalty income from Ivantis’ Hydrus Microstent expired April 2025, coinciding with competitor Alcon’s acquisition of Ivantis
- Financial risk: Accumulated deficit of $933.1 million as of December 31, 2025 with net losses of $187.7 million in 2025, reflecting ongoing unprofitability and high operating expenses
Management Discussion & Analysis
- Revenue $507.4M, up 32% YoY from $383.5M; US glaucoma sales up 50% to $298.6M, international glaucoma up 18% to $122.5M
- Gross margin 56% in 2025 vs 75% in 2024; Operating loss $(199.6)M vs $(122.4)M; Net loss $(187.7)M vs $(146.4)M
- Best segment US glaucoma sales $298.6M (+50%); Worst margin impacted by $112.9M intangible asset impairment, driving cost of sales 139% higher to $224.7M
- Cash/cash equivalents $90.8M; short-term investments $187.9M; operating cash used $14.8M; investing cash used $77.6M; financing cash provided $11.9M; $80M+ capex planned for Huntsville facility
- Management expects higher 2026 capex with Huntsville facility construction; key risk in funding operations as cash flows and profitability remain negative
AI summary of the GKOS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes from June 30, 2026 10-Q, per filing disclosure
- Regulatory risk: QMSR effective February 2, 2026, replacing FDA Quality System Regulation with ISO 13485:2016 requirements
- Near-term commercial risk: proposed LCDs from five MACs in May 2026 could impose conditions on iDose TR use
- Financial risk: accumulated deficit approximately $969.3 million, despite expected liquidity for at least 12 months
- Operational risk: sole San Clemente campus manufactures nearly all implanted device products, creating disruption concentration
Management Discussion & Analysis
- Revenue $211.0M, up 58% YoY from $133.5M, led by glaucoma and corneal health products
- Gross margin 85% vs 78% YoY, with net income $2.0M vs net loss $16.2M
- Best segment: corneal health revenue $59.0M, up 154% from $23.3M; international glaucoma worst growth, up 13% to $33.4M
- Cash flow: operating cash provided $40.9M vs $21.6M used YoY; cash, investments and restricted cash $339.8M vs $282.6M
- Outlook: $42.0M Huntsville Facility project, reimbursement uncertainty for potential iDose TR LCDs, Germany reimbursement challenges
AI summary of the GKOS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Investor Presentation intended for recurring discussions with investors and other stakeholders
- Exhibit 99.1 provides the substantive company disclosures and presentation materials
Item EX-99.1: Item EX-99.1
- November 2026 investor presentation highlights 14 pipeline programs and 12 commercialized products across glaucoma, cornea, eyelid and retina markets
- 2025 topline growth 30%, with 10-year revenue CAGR of 20% and $900 million invested in R&D since 2018
Item EX-99.1: Item EX-99.1
- Q3 net sales $211.0M, up 58%, led by Corneal Health growth of 154% and U.S. Glaucoma growth of 47%
- Gross margin expanded to 85.2% from 78.4%, supporting GAAP operating income of $0.8M versus a $16.4M loss
Item EX-99.2: Item EX-99.2
- Q3 revenue $211.0M, up 58%, with iDose TR sales approximately $76M and Epioxa sales approximately $53M
- Non-GAAP operating income $27.3M versus $9.3M loss, signaling operating leverage despite higher commercial and R&D investment
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Press release issued October 28, 2026, with results in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Quarterly Summary covers Glaukos’ third quarter ended September 30, 2026
- Supplemental business and financial information available in Exhibit 99.2
Item EX-99.1: Item EX-99.1
- Investor presentation outlines 13 pipeline programs and 12 commercialized products across glaucoma, cornea, retina and anterior-segment pharmaceuticals
- 2025 sales grew 30%, with 10-year revenue CAGR of 20% and $900 million invested in R&D since 2018
Item 7.01: Regulation FD Disclosure
- Investor Presentation covers Glaukos corporate and financial messaging for investor and stakeholder presentations
- Exhibit 99.1 available through SEC filing and Glaukos investor-relations website
AI summaries of GKOS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GKOS
Don't miss the next GKOS filing
- Alerts as it files. A push when GKOS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GKOS, by share count.
- Ask anything. An AI agent that reads every GKOS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Thurman Alex R. | Sell | Nov 18, 2026 | 2,021 | $237.43 |
| Thurman Alex R. | Sell | Nov 18, 2026 | 1,123 | $240.24 |
| Thurman Alex R. | Sell | Nov 18, 2026 | 1,493 | $233.62 |
| Thurman Alex R. | Sell | Nov 18, 2026 | 548 | $235.50 |
| Thurman Alex R. | Sell | Nov 18, 2026 | 1,190 | $238.26 |
| Thurman Alex R. | Sell | Nov 18, 2026 | 826 | $239.52 |
| Thurman Alex R. | M | Nov 18, 2026 | 15,000 | $45.71 |
| Thurman Alex R. | Sell | Nov 18, 2026 | 3,209 | $232.65 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $383.5M | $507.4M |
| Gross Profit | - | $289.5M | $282.8M |
| Operating Income | - | -$122.4M | -$199.6M |
| Net Income | - | -$146.4M | -$187.7M |
| Gross Margin | - | 75.5% | 55.7% |
| Op. Margin | - | -31.9% | -39.3% |
| Net Margin | - | -38.2% | -37.0% |
| Balance Sheet | |||
| Total Assets | $940.4M | $974.8M | $893.5M |
| Equity | $461.8M | $766.9M | $656.2M |
| ROE | - | -19.1% | -28.6% |
| Per Share | |||
| EPS | - | $-2.77 | $-3.28 |
| Cash Flow | |||
| Operating CF | - | -$61.3M | -$14.8M |
| CapEx | - | $6.3M | $7.7M |
Source: XBRL data in GLAUKOS Corp (GKOS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate GKOS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 33 | $4.29B |
| Q2 2026 | 34 | $3.94B |
| Q1 2026 | 33 | $3.02B |
| Q4 2025 | 29 | $3.11B |
| Q3 2025 | 31 | $2.08B |
| Q2 2025 | 28 | $3.18B |
| Q1 2025 | 27 | $2.20B |
| Q4 2024 | 24 | $3.17B |
- Invesco Ltd+528.4K (+75%)
- Goldman Sachs Group+128.9K (+14%)
- Renaissance Technologies LLC+121.5K (+83%)
- Franklin Resources+115.5K (+348%)
- Prudential Financial+57.5K (+41%)
- Ameriprise Financial−1.17M (-89%)
- Citadel Advisors LLC−1.05M (-76%)
- BlackRock−215.9K (-2%)
- Millennium Management−121.0K (-8%)
- T. Rowe Price Group−78.2K (-12%)
- FMR LLC (Fidelity)−377.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 239 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GKOS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 10-Q | Oct 28, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Aug 3, 2026 | - | - | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 21, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
GKOS SEC filings: frequently asked questions
Are GKOS insiders buying or selling?
In the last 90 days, GLAUKOS Corp (GKOS) officers, directors and 10% owners reported no open-market purchases and 56 open-market sales worth $72.0 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold GKOS stock?
As of September 30, 2026, the largest GLAUKOS Corp (GKOS) holders among the 13F filers tracked by SignalX were BlackRock ($1.5 billion), Vanguard Portfolio Management LLC ($542.5 million), Vanguard Capital Management LLC ($418.2 million), State Street Corp ($379.7 million), Millennium Management ($239.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GKOS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), GLAUKOS Corp (GKOS) reported revenue of $507.4 million (up 32.3% from FY2024) and a net loss of $187.7 million. Diluted EPS was -$3.28. The figures come from the XBRL data in the 10-K.
What are the main risks in GKOS's latest 10-K?
In the 10-K filed February 23, 2026, GLAUKOS Corp (GKOS) flagged: Regulatory risk: U.S. FDA approval of Epioxa in October 2025 requires securing permanent HCPCS J-Code and commercial payer coverage for reimbursement. Macroeconomic risk: U.S. tariffs on imports from Canada, Mexico, and China, despite limited exposure, risk escalating trade disputes affecting sourcing costs. (AI summary of the Risk Factors section.)
What did GKOS report in its latest 8-K?
GLAUKOS Corp (GKOS) filed an 8-K on November 6, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor Presentation intended for recurring discussions with investors and other stakeholders.
What are the latest GKOS SEC filings?
GLAUKOS Corp (GKOS) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on November 20, 2026.
What is GKOS's SEC CIK number?
GLAUKOS Corp (GKOS)'s SEC Central Index Key (CIK) is 1192448. EDGAR lists every GKOS filing under that number.
Ask anything about GKOS
The research agent reads GKOS's filings, financials, insider trades and 13F holders, then answers with sources.